Hair Loss Therapy

A physician-supervised hair loss treatment programme at ALPHALABS targeting androgenic alopecia (male-pattern baldness) driven by DHT. The clinic addresses hair thinning through a two-phase medical protocol: first blocking the dihydrotestosterone (DHT) pathway to stop further follicle miniaturisation, then stimulating regrowth through a physician-prescribed topical or oral treatment form selected to match each client's hair type, lifestyle and risk tolerance. Regular monitoring ensures efficacy and safety throughout the membership.

Hair loss at ALPHALABS is treated as a medical condition with a clear physiological mechanism, not a cosmetic inconvenience. The clinic's programme focuses specifically on androgenic alopecia — the most common form of male hair loss — which is driven by the conversion of testosterone to dihydrotestosterone (DHT) in hair follicles. DHT binds to androgen receptors in the scalp, progressively miniaturising follicles until they can no longer produce visible hair. The ALPHALABS approach targets this mechanism at the source. The programme begins with a physician consultation covering the client's hair loss history, family pattern, current rate of shedding, scalp condition and any previous treatments tried. A scalp and hair assessment determines the distribution and severity of miniaturisation (typically graded using the Norwood–Hamilton scale for men), which guides treatment selection and sets a baseline for progress measurement. Treatment follows a two-phase structure. Phase one uses a DHT-inhibiting agent to reduce circulating scalp DHT levels, thereby halting the continued miniaturisation of susceptible follicles. Phase two introduces a follicle-stimulating component to encourage regrowth in recently dormant follicles. The physician chooses between two delivery forms: a topical solution (applied directly to the scalp, lower systemic exposure, marginally less potent) or oral tablets (higher systemic efficacy, requires closer monitoring for systemic effects). In some cases, both are combined. The form is not predetermined — it is selected based on the client's scalp type, hair distribution, lifestyle factors and any risk considerations the physician identifies during intake. Monthly clinic visits serve as both monitoring appointments and treatment reviews. The physician assesses the rate and distribution of shedding versus regrowth, checks relevant blood markers (including hormonal panel and liver enzymes when oral agents are used), and adjusts dose or delivery form if the response is sub-optimal. Clients are counselled that visible results typically require several months — hair follicle cycling operates on a 3–6-month growth phase, so patience and consistency are essential. Results are maintained only as long as therapy continues, which is discussed transparently at the outset. The programme is primarily designed for men with androgenic alopecia but may be suitable for certain women experiencing hormonal hair thinning — assessed case by case at the initial consultation. Contraindications include pregnancy (for the oral form) and specific cardiovascular conditions.